Biotechnology firm Ocugen (NASDAQ:OCGN) — which specializes in developing gene therapies to address blindness diseases — saw its shares move higher on an encouraging clinical development. An advisory committee responsible for overseeing safety matters approved Ocugen to use a medium dosage of its retinal therapeutic. Subsequently, OCGN stock moved higher on the positive implications. According to the company’s press release, Ocugen received a green light from the Data and Safety Monitoring Board (DSMB) for ...